1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study ...
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37% to 70% ...
1. A randomized controlled trial of patients with stage II and III rectal cancer found that adding oxaliplatin to the ...
1. Although combining pembrolizumab to chemoradiotherapy as part of total neoadjuvant therapy after FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) treatment was ...
1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first ...
1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative ...
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX ...
1. In a phase II trial of T3 resectable rectal cancer, adding bevacizumab to induction and neoadjuvant chemoradiation resulted in ...
Image: PD 1. Early enteral nutrition (EEN) resulted in shorter time to first defecation after rectal resection for cancer and ...
Image: PD/Navy 1. Patients with mesorectal invasion of more than 5mm and sacral-side involvement (seen on MRI) demonstrated higher rates ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.